NeoGenomics, Inc. finalized a civil settlement with the U.S. Department of Justice to resolve an investigation into consulting services provided to healthcare providers. The company agreed to pay $9,813,260 plus 4.250% annual interest from January 16, 2026, to resolve the matter, utilizing a previously accrued reserve of $11.2 million. NeoGenomics is a cancer diagnostics company specializing in cancer genetics testing and information services.
